J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

Johnson & Johnson is due to report Q3 2026 results on Oct. 13, with consensus sales of $25.37 billion and EPS of $2.66; earnings estimates for 2026 and 2027 have fallen over the past 60 days. Growth in Innovative Medicine and newer launches is expected to offset Stelara biosimilar pressure, while MedTech faces softness in parts of Cardiovascular. Shares are up 24% year to date, but trade at 20.70 times forward earnings versus 18.03 for the industry; the article recommends staying invested.

Analysis

The setup is asymmetric into the Oct. 13 report: the stock has rerated, while forward earnings estimates have been cut. A small beat may therefore have limited upside unless guidance and product-level detail restore confidence in the growth trajectory. The key test is not headline EPS but whether new-product growth and non-Stelara demand can offset the accelerating erosion in Stelara, Imbruvica and other exposed products without relying on optimistic launch assumptions.

The second-order risk is that biosimilar substitution can expand the market while still producing weak economics for suppliers: share gains at AMGN, TEVA and Sandoz do not automatically translate into attractive revenue if price and payer concessions intensify. Conversely, JNJ’s reported growth excluding Stelara can overstate underlying durability if the replacement portfolio is concentrated in a few launch-stage drugs. MedTech is another swing factor: continued weakness in cardiovascular would undermine the expected second-half recovery even if other businesses improve.

Over days, earnings and guidance can drive a valuation reset; over 1–3 months, launch uptake, biosimilar share/price trends and MedTech execution matter more than a one-quarter beat. The contrarian risk is that the market may be treating the patent cliff as a known, manageable headwind while underpricing the execution burden of replacing it. Reassess if management raises the outlook and provides evidence of broad-based growth; the thesis weakens if guidance is maintained only on launch optimism or MedTech recovery slips.

Key Decisions for Investors

• Avoid adding JNJ ahead of the print after its rerating; for existing positions, consider trimming to a neutral weight rather than making a large outright short. The earnings-revision direction and valuation premium leave less room for a routine beat to surprise positively.
• Use the report as a trigger, not a prediction: add only if guidance is supported by product-level evidence of launch contribution and stable underlying growth, and MedTech shows a credible recovery. Verify segment sales, launch uptake, Stelara erosion and the outlook for cardiovascular.
• For a relative-value expression, consider a modest underweight in JNJ versus a diversified healthcare benchmark rather than a direct short of AMGN, TEVA or Sandoz. Biosimilar competition may benefit those suppliers, but pricing and share data are needed before treating them as clean Stelara winners.
• Falsify the cautious view if JNJ raises its outlook and demonstrates broad-based growth beyond a small set of launches; strengthen it if guidance is cut, Stelara erosion accelerates beyond expectations, or MedTech recovery is delayed. Revisit after the call and the next 1–3 months of launch and segment data.